Results of Phase Ib/II study of ricolinostat in multiple myeloma
Why daratumumab will become key for the treatment of multiple myeloma
Results of Phase III POLLUX trial on daratumumab in multiple myeloma
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?